A clinical study comparing topotecan plus carboplatin versus etoposide plus carboplatin for previ-ously untreated small cell lung cancer / 中国医师进修杂志
Chinese Journal of Postgraduates of Medicine
;
(36): 4-6, 2008.
Artículo
en Chino
| WPRIM
| ID: wpr-400690
ABSTRACT
Objective To assess the efficacy and toxicity of topoteean hydllochloride plus carbo-platin(TC)versus etoposide plus carboplatin(CE)in patients for previously untreated small cell lung cancer (SCLC).Methods Sixty-nine patients with previously untreated SCLC,TC group(34 eases)were treated with topotecan 1 mg/m2 from day 1 to day 5 and carboplatin 300 mg/m2on day 1.CE group(35 cases)were treated with etoposide 100 mg/d from day 1 to day 5 and carboplatin 300 mg/m2 on day 1.Treatment was repeated every 3 weeks.The efficacy and toxicity were ev Mumed in patients who received two cvcles of chemotherapy.ResMN The total effective rate Was 76.5%in TC group and 71.4%in CE group(P>0.05). The progression-free survival interval was 4.1 months in TC group and 2.6 months in CE group(P<0.05). There was no significant difference in the most common toxieities between two groups(P>0.05).Conclusion Compared with etoposide plus carboplatin,topotecan plus carboplatin has similar total effective rate,and in- different toxieities,and the longer progression-free survival interval,so it is a safe and effective first-line treatment for SCLC.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Postgraduates of Medicine
Año:
2008
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS